---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-24-006996"
form_type: "8-K"
ticker: "BGLC"
cik: "0001737523"
company_name: "BioNexus Gene Lab Corp"
filed_at: "2024-11-08T23:59:59+00:00"
generated_at: "2026-05-30T02:54:17.045211+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BioNexus Gene Lab receives Nasdaq delisting notice; appeals with compliance plan including reverse stock split

## Summary
- Received delisting notice on Nov 5, 2024 for failing to maintain minimum $1 bid price after two 180-day grace periods ended Nov 4.
- Filed appeal on Nov 8, 2024; hearing stays trading suspension pending Panel decision.
- Intends to present compliance plan including potential reverse stock split to regain listing compliance.
- Appointed Jook Yuen Low as independent director effective Nov 5, assigned to Audit and Nomination committees.
- Re-appointed Su-Leng Tan Lee as Secretary and appointed as President; no compensation change.

## SEC filing metadata
- accession: 0001477932-24-006996
- form_type: 8-K
- ticker: BGLC
- cik: 0001737523
- company_name: BioNexus Gene Lab Corp
- filed_at: 2024-11-08T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737523/000147793224006996/0001477932-24-006996-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737523/000147793224006996/bglc_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-24-006996
- JSON: https://secwatch.observer/filing/0001477932-24-006996.json
- Plain text: https://secwatch.observer/filing/0001477932-24-006996.txt

## Key facts
- Executive change
  Su-Leng Tan Lee was appointed as President at BioNexus Gene Lab Corp.
  - Action: appointed as President
  - Role: President
  source text: Additionally, the Board has re-appointed Mr. Su-Leng Tan Lee as Secretary of the Company and has appointed him as President, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737523/000147793224006996/0001477932-24-006996-index.htm
- Executive change
  Jook Yuen Low was appointed as Director at BioNexus Gene Lab Corp.
  - Action: appointed
  - Role: Director
  source text: On November 5, 2024, the Board of Directors of the Company appointed Ms. Jook Yuen Low as an independent director to the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737523/000147793224006996/0001477932-24-006996-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.